Soluble factor and cell-cell interaction in cytostasis induced by bone marrow cells

Senyukov, Vladimir; Селедцов, В. И.; Повещенко, О. В.; Taraban, Vadim Y.; Козлов, В. А.

doi:10.1007/bf02434876

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,22 Before identification of MSC as a distinct cell type, reports exist of a bone marrow-derived non-cytotoxic tumor inhibitor of a low molecular weight, capable of inducing G 0 arrest/ apoptosis of various tumor cells, 23,24 as well as inhibiting tumor growth in vivo. 25,26 In our experiments we observed a profound inhibition of C6 glioma cells in animals treated with ERC either i.v. or i.t.. Suppression of tumor growth was not associated with necrosis but characterize by lower number of new blood vessels as identified morphologically and by anti-CD34 staining.…”

Section: Discussionmentioning

confidence: 93%

Inhibition of intracranial glioma growth by endometrial regenerative cells

Han¹,

Meng²,

Yin³

et al. 2009

Cell Cycle

View full text Add to dashboard Cite

Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads. Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production. In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/LacZ7 (C6) into Sprague Dawley rat model. ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49% after i.v. treatment (p < 0.05), and about 46% i.t. treatment (p < 0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor. Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC. Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.

show abstract

Section: Discussionmentioning

confidence: 93%

Inhibition of intracranial glioma growth by endometrial regenerative cells

Han¹,

Meng²,

Yin³

et al. 2009

Cell Cycle

View full text Add to dashboard Cite

show abstract

“…Therefore, the initiation of tumor growth is supported primarily by reciprocal tumor cell-dependent (but not tumor-normal cell-dependent) contacts. We envisage that it is a pronounced immune cell infiltration of the tumor that is the major factor limiting tumor growth, wherein immune cells control tumor growth via contact-dependent intercommunications and the production of cytostatic/cytotoxic factors [ 46 ]. In agreement, tumor infiltration by immune cells, and most notably T cells, is considered to be a positive prognostic factor [ 13 ].…”

Section: Role Of Immunotherapy In Multimodal Multipurpose Treatment O...mentioning

confidence: 99%

Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

Tumor growth and expansion are determined by the immunological tumor microenvironment (TME). Typically, early tumorigenic stages are characterized by the immune system not responding or weakly responding to the tumor. However, subsequent tumorigenic stages witness the tumor promoting its growth and metastasis by stimulating tumor-protective (pro-tumor) inflammation to suppress anti-tumor immune responses. Here, we propose the pivotal role of inflammation control in a successful anti-cancer immunotherapy strategy, implying that available and novel immunotherapeutic modalities such as inflammation modulation, antibody (Ab)-based immunostimulation, drug-mediated immunomodulation, cancer vaccination as well as adoptive cell immunotherapy and donor leucocyte transfusion could be applied in cancer patients in a synergistic manner to amplify each other’s clinical effects and achieve robust anti-tumor immune reactivity. In addition, the anti-tumor effects of immunotherapy could be enhanced by thermal and/or oxygen therapy. Herein, combined immune-based therapy could prove to be beneficial for patients with advanced cancers, as aiming to provide long-term tumor cell/mass dormancy by restraining compensatory proliferation of surviving cancer cells observed after traditional anti-cancer interventions such as surgery, radiotherapy, and metronomic (low-dose) chemotherapy. We propose the Inflammatory Prognostic Score based on the blood levels of C-reactive protein and lactate dehydrogenase as well as the neutrophil-to-lymphocyte ratio to effectively monitor the effectiveness of comprehensive anti-cancer treatment.

show abstract

Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer

Селедцов

Delwig

2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Soluble factor and cell-cell interaction in cytostasis induced by bone marrow cells

Abstract: Cell-cell interaction and soluble low-molecular-weight products are probably involved in in vitro inhibition of leukemic cell growth by bone marrow cells.

Cited by 3 publications

References 9 publications

Inhibition of intracranial glioma growth by endometrial regenerative cells

Inhibition of intracranial glioma growth by endometrial regenerative cells

Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment

Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer

Contact Info

Product

Resources

About